Initial Treatment of B-cell Acute Lymphoblastic Leukemia (ALL)
Treatment Approach by Age and Fitness
- The National Comprehensive Cancer Network recommends initiating intensive multiagent induction chemotherapy with a backbone of vincristine, anthracycline, corticosteroid, and L-asparaginase for adults under 65 years with newly diagnosed B-cell ALL 1, 2, 3
- For adults under 65 years, induction regimens should include a 4-drug backbone, with specific evidence-based options including CALGB 9111, ECOG 1910, or dose-adjusted Hyper-CVAD, classified as high-intensity regimens by NCCN 1
- Modified DFCI 91-01, GMALL, GRAALL, or EWALL regimens are moderate-intensity alternatives for adults under 65 years 1
- The National Comprehensive Cancer Network suggests adding rituximab to GMALL for CD20-positive disease in adults under 65 years 1
Critical Treatment Components
- The National Comprehensive Cancer Network recommends intrathecal chemotherapy from the start, with triple intrathecal therapy preferred over methotrexate alone for CNS prophylaxis 1, 2, 5
- Prophylactic cranial irradiation is not recommended for B-ALL in the context of effective systemic and intrathecal therapy 5
- Dexamethasone provides superior CNS penetration and reduces CNS relapse risk, but carries higher risks of induction mortality, neuropsychiatric events, and myopathy 3
Minimal Residual Disease (MRD) Monitoring
- The National Comprehensive Cancer Network mandates MRD assessment after induction, guiding subsequent treatment decisions 1, 2, 4
- MRD-negative patients should proceed with standard consolidation and maintenance, while MRD-positive or rising patients should add blinatumomab or inotuzumab ozogamicin before consolidation 1, 4
- Blinatumomab achieves 88% complete MRD response in patients with MRD ≥10⁻³ 4
High-Risk Features Requiring Treatment Intensification
- The National Comprehensive Cancer Network identifies high-risk features requiring treatment intensification, including age ≥35 years, WBC >30 × 10⁹/L, time to complete remission >4 weeks, poor-risk cytogenetics, and molecular alterations 1, 2, 3, 6
- For these patients, consider allogeneic hematopoietic cell transplantation in first complete remission 6